Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


E. Fougera OTCs

This article was originally published in The Tan Sheet

Executive Summary

Consumer Products Division will introduce three new OTC products in first aid, athlete's foot areas by mid-2003, company says. Three products will not be Rx switches, but Fougera is "considering additional original developments, transfers from the main line and Rx-to-OTC switch candidates" in the future. Two of newly created division's three original products - HydroZone Plus 1% (hydrocortisone lotion) and babyADE A&D + vitamin E diaper rash ointment - were "an extension of Fougera's Rx experience," firm notes (1"The Tan Sheet" June 3, 2002, In Brief)...

You may also be interested in...

babyADE ointment

E. Fougera & Co., which makes ointments and ophthalmics for the institutional market, continues its foray into the OTC arena with launch of babyADE A&D + Vitamin E diaper rash ointment. Fougera hopes addition of vitamin E to its standard A&D ointment will "attract health aware parents" and "allow mothers to continue using the diaper rash ointment they were introduced to in the hospital after they go home." Hitting independent drugstore shelves now, babyADE is available in 2 oz. tubes for $3.99-$4.99, 4 oz. tubes for $5.49-$6.99. Firm notes "deals are imminent" to launch ointment in two major national drug chains, with national distribution expected by early 2003...

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts